LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

By LabMedica International staff writers
Posted on 07 Jun 2016
Print article
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).
Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells.

The three-dimensional print electronics developer Nano Dimension (Ness Ziona, Israel) collaborated with Accellta (Haifa, Israel), which has developed proprietary technologies for the production of high quality media, stem cells, progenitors, and differentiated cells for drug discovery, regenerative medicine, and research.

The partners recently announced that they had successfully tested a proof-of-concept three-dimensional bioprinter for stem cells. The ability of the printer to generate stem cells was due in part to Accellta's robust and reproducible suspension-based cell culturing systems that produce billions of high quality stem cells per batch.

Amit Dror, CEO of Nano Dimension, said, "Three-dimensional printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control, and viability as well as cell availability and bio-ink technologies. By combining our high speed, high precision inkjet capabilities with Accellta's stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable three-dimensional printing at high resolution and high volumes."

Dr. Itzchak Angel, CEO of Accellta, said, "Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies. We hope and believe that this will bring the mutual capabilities and know-how of both companies to create three-dimensional bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision three-dimensional bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development."

Related Links:
Nano Dimension
Accellta
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more